Compare GNLN & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNLN | VRAX |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Durable Goods | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6M | 1.7M |
| IPO Year | 2019 | 2021 |
| Metric | GNLN | VRAX |
|---|---|---|
| Price | $0.30 | $0.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 284.6K | ★ 5.6M |
| Earning Date | 05-14-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,275,000.00 | N/A |
| Revenue This Year | $1,541.21 | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.01 | $0.15 |
| 52 Week High | $7.73 | $1.34 |
| Indicator | GNLN | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 26.61 | 41.28 |
| Support Level | N/A | N/A |
| Resistance Level | $0.89 | $0.25 |
| Average True Range (ATR) | 0.12 | 0.02 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 6.58 | 10.71 |
Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.